The VD1 neutralizing antibody to vascular endothelial growth factor-D: Binding epitope and relationship to receptor binding

Journal of Molecular Biology

Volumn 407, Issue 4, 2011, Pages 581-593

  Davydova, Natalia ^a,b   Roufail, Sally ^a,b   Streltsov, Victor A ^c   Stacker, Steven A ^a,b   Achen, Marc G ^a,b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c CSIRO   (Australia)

Author keywords

cancer; mutagenesis; structure function; therapeutics; VEGF D

Indexed keywords

EPITOPE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VD1 NEUTRALIZING ANTIBODY;

ARTICLE; BINDING SITE; CONTROLLED STUDY; MUTATION; PEPTIDE MAPPING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN TERTIARY STRUCTURE; RECEPTOR BINDING; SITE DIRECTED MUTAGENESIS;

ANIMALIA;

EID: 79952456041     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2011.02.009     Document Type: Article

References (51)

1. Achen M.G., Jeltsch M., Kukk E., Makinen T., Vitali A., and Wilks A.F. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4) Proc. Natl Acad. Sci. USA 95 1998 548 553 (Pubitemid 28083780)
2. Lohela M., Bry M., Tammela T., and Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis Curr. Opin. Cell Biol. 21 2009 154 165
3. Stacker S.A., Caesar C., Baldwin M.E., Thornton G.E., Williams R.A., and Prevo R. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics Nat. Med. 7 2001 186 191 (Pubitemid 32148485)
4. Veikkola T., Jussila L., Makinen T., Karpanen T., Jeltsch M., and Petrova T.V. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice EMBO J. 20 2001 1223 1231 (Pubitemid 32233963)
5. Rissanen T.T., Markkanen J.E., Gruchala M., Heikura T., Puranen A., and Kettunen M.I. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses Circ. Res. 92 2003 1098 1106 (Pubitemid 36665855)
6. Byzova T.V., Goldman C.K., Jankau J., Chen J., Cabrera G., and Achen M.G. Adenovirus encoding vascular endothelial growth factor-D induces tissue-specific vascular patterns in vivo Blood 99 2002 4434 4442 (Pubitemid 34627212)
7. Bhardwaj S., Roy H., Gruchala M., Viita H., Kholova I., and Kokina I. Angiogenic responses of vascular endothelial growth factors in periadventitial tissue Hum. Gene Ther. 14 2003 1451 1462 (Pubitemid 37268223)
8. Baldwin M.E., Stacker S.A., and Achen M.G. Molecular control of lymphangiogenesis BioEssays 24 2002 1030 1040 (Pubitemid 35326161)
9. Wise L.M., Ueda N., Dryden N.H., Fleming S.B., Caesar C., and Roufail S. Viral vascular endothelial growth factors vary extensively in amino acid sequence, receptor-binding specificities, and the ability to induce vascular permeability yet are uniformly active mitogens J. Biol. Chem. 278 2003 38004 38014 (Pubitemid 37175331)
10. Baldwin M.E., Halford M.M., Roufail S., Williams R.A., Hibbs M.L., and Grail D. Vascular endothelial growth factor D is dispensable for development of the lymphatic system Mol. Cell. Biol. 25 2005 2441 2449 (Pubitemid 40354637)
11. Haiko P., Makinen T., Keskitalo S., Taipale J., Karkkainen M.J., and Baldwin M.E. Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos Mol. Cell. Biol. 28 2008 4843 4850
12. Ny A., Koch M., Vandevelde W., Schneider M., Fischer C., and Diez-Juan A. Role of VEGF-D and VEGFR-3 in developmental lymphangiogenesis, a chemicogenetic study in Xenopus tadpoles Blood 112 2008 1740 1749
13. Achen M.G., Williams R.A., Minekus M.P., Thornton G.E., Stenvers K., and Rogers P.A. Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis J. Pathol. 193 2001 147 154 (Pubitemid 32118124)
14. Rutanen J., Leppanen P., Tuomisto T.T., Rissanen T.T., Hiltunen M.O., and Vajanto I. Vascular endothelial growth factor-D expression in human atherosclerotic lesions Cardiovasc. Res. 59 2003 971 979 (Pubitemid 38366253)
15. Von Marschall Z., Scholz A., Stacker S.A., Achen M.G., Jackson D.G., and Alves F. Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer Int. J. Oncol. 27 2005 669 679
16. Kopfstein L., Veikkola T., Djonov V.G., Baeriswyl V., Schomber T., and Strittmatter K. Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis Am. J. Pathol. 170 2007 1348 1361 (Pubitemid 47339341)
17. Achen M.G., and Stacker S.A. Tumor lymphangiogenesis and metastatic spread-new players begin to emerge Int. J. Cancer 119 2006 1755 1760 (Pubitemid 44356830)
18. White J.D., Hewett P.W., Kosuge D., McCulloch T., Enholm B.C., Carmichael J., and Murray J.C. Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma Cancer Res. 62 2002 1669 1675 (Pubitemid 34408487)
19. Yokoyama Y., Charnock-Jones D.S., Licence D., Yanaihara A., Hastings J.M., and Holland C.M. Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma Br. J. Cancer 88 2003 237 244 (Pubitemid 36255842)
20. Stearns M.E., Wang M., Hu Y., Kim G., and Garcia F.U. Expression of a flt-4 (VEGFR3) splicing variant in primary human prostate tumors. VEGF D and flt-4t(Delta773-1081) overexpression is diagnostic for sentinel lymph node metastasis Lab. Invest. 84 2004 785 795 (Pubitemid 38715478)
21. Achen M.G., and Stacker S.A. Molecular control of lymphatic metastasis Ann. N. Y. Acad. Sci. 1131 2008 225 234 (Pubitemid 351758517)
22. Jubb A.M., and Harris A.L. Biomarkers to predict the clinical efficacy of bevacizumab in cancer Lancet Oncol. 11 2010 1172 1183
23. Seyama K., Kumasaka T., Kurihara M., Mitani K., and Sato T. Lymphangioleiomyomatosis: a disease involving the lymphatic system Lymphat. Res. Biol. 8 2010 21 31
24. Seyama K., Kumasaka T., Souma S., Sato T., Kurihara M., and Mitani K. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis Lymphat. Res. Biol. 4 2006 143 152 (Pubitemid 46070353)
25. Glasgow C.G., Avila N.A., Lin J.P., Stylianou M.P., and Moss J. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement Chest 135 2009 1293 1300
26. McColl B.K., Paavonen K., Karnezis T., Harris N.C., Davydova N., and Rothacker J. Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2 FASEB J. 21 2007 1088 1098 (Pubitemid 46495698)
27. Stacker S.A., Stenvers K., Caesar C., Vitali A., Domagala T., and Nice E. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers J. Biol. Chem. 274 1999 32127 32136
28. Achen M.G., Roufail S., Domagala T., Catimel B., Nice E.C., and Geleick D.M. Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3. Eur. J. Biochem. 267 2000 2505 2515 (Pubitemid 30304244)
29. Kubo H., Fujiwara T., Jussila L., Hashi H., Ogawa M., and Shimizu K. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis Blood 96 2000 546 553 (Pubitemid 30463374)
30. He Y., Kozaki K., Karpanen T., Koshikawa K., Yla-Herttuala S., Takahashi T., and Alitalo K. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling J. Natl Cancer Inst. 94 2002 819 825 (Pubitemid 34705053)
31. He Y., Rajantie I., Pajusola K., Jeltsch M., Holopainen T., and Yla-Herttuala S. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels Cancer Res. 65 2005 4739 4746 (Pubitemid 40740810)
32. Lin J., Lalani A.S., Harding T.C., Gonzalez M., Wu W.W., and Luan B. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor Cancer Res. 65 2005 6901 6909 (Pubitemid 41060729)
33. Laakkonen P., Waltari M., Holopainen T., Takahashi T., Pytowski B., and Steiner P. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth Cancer Res. 67 2007 593 599 (Pubitemid 46192197)
34. Baldwin M.E., Catimel B., Nice E.C., Roufail S., Hall N.E., and Stenvers K.L. The specificity of receptor binding by vascular endothelial growth factor-d is different in mouse and man J. Biol. Chem. 276 2001 19166 19171
35. Stacker S.A., and Achen M.G. The vascular endothelial growth factor family: signalling for vascular development Growth Factors 17 1999 1 11 (Pubitemid 29435870)
36. Leppanen V.M., Jeltsch M., Anisimov A., Tvorogov D., Aho K., and Kalkkinen N. Structural determinants of vascular endothelial growth factor-D receptor binding and specificity Blood 117 2010 1507 1515
37. Muller Y.A., Christinger H.W., Keyt B.A., and de Vos A.M. The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 Å resolution: multiple copy flexibility and receptor binding Structure 5 1997 1325 1338 (Pubitemid 27484475)
38. Iyer S., Leonidas D.D., Swaminathan G.J., Maglione D., Battisti M., and Tucci M. The crystal structure of human placenta growth factor-1 (PlGF-1), an angiogenic protein, at 2.0 Å resolution J. Biol. Chem. 276 2001 12153 12161
39. Iyer S., Scotney P.D., Nash A.D., and Ravi Acharya K. Crystal structure of human vascular endothelial growth factor-B: identification of amino acids important for receptor binding J. Mol. Biol. 359 2006 76 85
40. Leppanen V.M., Prota A.E., Jeltsch M., Anisimov A., Kalkkinen N., and Strandin T. Structural determinants of growth factor binding and specificity by VEGF receptor 2 Proc. Natl Acad. Sci. USA 107 2010 2425 2430
41. Kim K.J., Li B., Houck K., Winer J., and Ferrara N. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies Growth Factors 7 1992 53 64
42. Fuh G., Wu P., Liang W.C., Ultsch M., Lee C.V., Moffat B., and Wiesmann C. Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab J. Biol. Chem. 281 2006 6625 6631 (Pubitemid 43847597)
43. Muller Y.A., Chen Y., Christinger H.W., Li B., Cunningham B.C., Lowman H.B., and de Vos A.M. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 Å resolution and mutational analysis of the interface Structure 6 1998 1153 1167 (Pubitemid 28434118)
44. Ferrara N., Hillan K.J., and Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy Biochem. Biophys. Res. Commun. 333 2005 328 335 (Pubitemid 40848295)
45. Leonard P., Scotney P.D., Jabeen T., Iyer S., Fabri L.J., Nash A.D., and Acharya K.R. Crystal structure of vascular endothelial growth factor-B in complex with a neutralising antibody Fab fragment J. Mol. Biol. 384 2008 1203 1217
46. Guex N., and Peitsch M.C. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling Electrophoresis 18 1997 2714 2723 (Pubitemid 28059943)
47. Schwede T., Kopp J., Guex N., and Peitsch M.C. SWISS-MODEL: an automated protein homology-modeling server Nucleic Acids Res. 31 2003 3381 3385 (Pubitemid 37442164)
48. Arnold K., Bordoli L., Kopp J., and Schwede T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling Bioinformatics 22 2006 195 201 (Pubitemid 43205406)
49. van Gunsteren W.F., Billeter S.R., Eising A., Hünenberger P.H., Krüger P., and Mark A.E. Biomolecular Simulations: The GROMOS96 Manual and User Guide 1996 VdF Hochschulverlag ETHZ Zürich Zürich, Switzerland
50. Melo F., and Feytmans E. Assessing protein structures with a non-local atomic interaction energy J. Mol. Biol. 277 1998 1141 1152 (Pubitemid 28190852)
51. DeLano W.L. The PyMOL Molecular Graphics System 2002 DeLano Scientific San Carlos, CA